Drugs / UTAA07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07338604 | Dec 2025 → Dec 2027 expected | hematopoietic and lymphoid cell neoplasm | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA07 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07338604 ↗ |
| Known as | UTAA07 Injection | “UTAA07 Injection is a chimeric antigen receptor (CAR)-engineered γδ T-cell product that targets the CD7 antigen expressed on the surface of tumor cells.” NCT07338604 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR)-engineered γδ T-cell product” NCT07338604 ↗ |
| Target | CD7 | “targets the CD7 antigen expressed on the surface of tumor cells.” NCT07338604 ↗ |